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Highly active antiretroviral therapy (HAART) has signiﬁcantly increased life expectancy of
the human immunodeﬁciency virus (HIV)-positive population. Nevertheless, the average
lifespan of HIV-patients remains shorter compared to uninfected individuals. Immunose-
nescence, a current explanation for this difference invokes heavily on viral stimulus despite
HAART efﬁciency in viral suppression.We propose here that the premature and accelerated
aging of HIV-patients can also be caused by adverse effects of antiretroviral drugs, specif-
ically those that affect the mitochondria. The nucleoside reverse transcriptase inhibitor
(NRTI) antiretroviral drug class for instance, is known to cause depletion of mitochondrial
DNA via inhibition of the mitochondrial speciﬁc DNA polymerase-γ. Besides NRTIs, other
antiretroviral drug classes such as protease inhibitors also cause severe mitochondrial
damage by increasing oxidative stress and diminishing mitochondrial function. We also
discuss important areas for future research and argue in favor of the use of Caenorhabditis
elegans as a novel model system for studying these effects.
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HIV-INFECTION
The human immunodeﬁciency virus (HIV-1) is a Retrovirus of the
Lentivirus genus that primarily infects cells of the host immune
system. Once an individual is infected, HIV-1 replication takes
place in several steps. In the ﬁrst step, the virion attaches itself
to the host cell with the help of co-receptors, whereupon it fuses
with the host cell membrane and the two single-stranded RNA
molecules and three different viral enzymes are released into the
host cell cytoplasm. The viral reverse transcriptase transcribes the
viral RNA into DNA, at which point the viral DNA is transported
into the nucleus. With the aid of the viral integrase the viral DNA
is processed and incorporated into the host genome. The inte-
grated viral DNA, now known as a provirus, is transcribed and
translated by the host machinery to synthesize viral proteins and
single-strandedRNA for new virions. After assembly of these com-
ponents at the plasma membrane, the new virions bud off and
mature using the viral protease, completing the HIV-1 life cycle
(Figure 1; Teixeira et al., 2011). HIV infection of host immune
cells causes them to die and thus drastically deplete in number. As
immune cell counts decline, the host gradually becomes immune-
incompetent and more susceptible to opportunistic infections. If
untreated, this leads to acquired immune deﬁciency syndrome
(AIDS) and eventually death.
ANTIRETROVIRAL THERAPY
For the treatment of HIV-1 infection there are currently six dif-
ferent classes of anti-HIV drugs. Each class of drug acts on a
particular aspect of the viral life cycle (Figure 1), and are used
in unison to increase therapy efﬁcacy, overcome problems of tol-
erance, and decrease emergence of viral resistance. The major
classes include the entry inhibitors (EIs), the nucleoside reverse
transcriptase inhibitors (NRTIs), the non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), and the protease inhibitors (PIs).
The additional two anti-HIV drug classes are the maturation
inhibitors (MIs) and integrase inhibitors (IIs), of which most
compounds are still in clinical development.
Since 1996 the combination of at least three antiviral drugs,
preferably from at least two different classes, has become stan-
dard practice and is known as highly active antiretroviral therapy
(HAART).Due to the large variety in drug combinations, standard
HAART has been deﬁned as one or more NRTIs combined with a
PI (Table 1) and often supplemented with one drug from another
class (Dybul et al., 2002). Due to the replicative speed of HIV-1 and
the inability of antiretroviral drugs to eradicate infection, patients
need to medicate daily for the rest of their lives. Nonetheless, the
therapeutic use of a combination of drugs was a major advance in
HIV therapy and has signiﬁcantly improved the quality and length
of patient lives.
HAART TREATED HIV-PATIENTS AGE PREMATURELY
Without antiretroviral therapy HIV-infected patients usually die
within years because of immune system failure. Due to HAART
however, early death is prevented, allowing HIV-patients to
live decades as long medication is continued (May and Ingle,
2011). It was recently estimated that more than 50% of HIV-
infected patients in the United States will be over the age of
50 in 2015 (Effros et al., 2011). Even though this gain in lifes-
pan is celebrated as a success, data show that the life expectancy
of treated patients remains shorter than that of the normal
population (The Antiretroviral Therapy Cohort Collaboration,
2008). Life expectancy for treated HIV-patients is dependent
on the age at which antiretroviral therapy is started and is
estimated to be 10–30 years less than that of the uninfected
(Lohse et al., 2007). Several studies have also observed that
co- and multi-morbidities, like cardiovascular disease, diabetes,
and osteoporosis, which are normally witnessed later on in
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FIGURE 1 |The HIV-1 life cycle and the antiretroviral drug class
intervention points. Entry inhibitors interfere with viral entry into the host
cell and are comprised of a complex group of drugs with multiple
mechanisms of action. By inhibiting several key proteins that mediate the
process of virion attachment, co-receptor binding and fusion, virus spreading
can be mitigated (Tilton and Doms, 2010). NRTIs imitate endogenous
deoxyribonucleotides and have a high afﬁnity for the viral reverse
transcriptase, thus facilitating incorporation into the viral DNA strand during
synthesis. NRTI incorporation results in transcription termination as they all
lack the 3′-OH group necessary for phosphodiester bond formation in DNA
strand elongation (Cihlar and Ray, 2010). NNRTIs are compounds that ﬁt into
the allosteric “pocket” site of the HIV-1 reverse transcriptase and disrupt its
enzymatic activity, selectively blocking HIV-1 transcription (De Clercq, 2004).
Integrase inhibitors bind cofactors of the viral integrase that are essential in
host DNA interaction and therefore block insertion of proviral DNA into the
host genome (Schafer and Squires, 2010). Protease inhibitors bind the viral
protease active site with high afﬁnity and therefore inhibit cleavage of viral
polypeptides and subsequent maturation of the virion after budding from the
host cell (Adamson, 2012). HIV-1 maturation inhibitors act much like protease
inhibitors in that they inhibit the processing of the HIV-1 polypeptides.
However, maturation inhibitors do not bind the protease but rather the
polypeptide itself, rendering it uncleavable (Richards and McCallister, 2008).
The relative size of different components has been altered for pictorial
clarity.
life as a result of natural aging, were increasingly prominent
among the HIV-infected population (Deeks and Phillips, 2009;
Guaraldi et al., 2011). These observations led to the hypothesis
that the HAART treated HIV-infected population is aging more
rapidly, a phenomenon now known as premature and accelerated
aging.
THEORIES FOR PREMATURE AND ACCELERATED AGING IN
HAART TREATED PATIENTS
There are several factors that inﬂuence lifespan of the HIV-
infected, but have limited effects on progression of premature and
accelerated aging phenotypes. These include lifestyle risk factors
such as smoking, drinking, and illicit drug use, which are preva-
lent across the HIV-infected population (Shurtleff and Lawrence,
2012). Illicit drug use for example, is associated with poorer medi-
cation adherence and lesser immunological and virological control
(Lucas et al., 2001). Additionally, co-infection, such as with viral
hepatitis, is common among the HIV-infected population and
is known to decrease life expectancy (Sulkowski, 2008). HIV-1
patients also run a greater risk for adverse drug interactions due to
the increase in “pill-burden” to combat co-morbidities (Marzolini
et al., 2011). Moreover, both natural aging or HIV-1 infection
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Table 1 | Antiretroviral drugs discussed in this review.
Antiretroviral
drug class
Drug name Other names/abbreviations
Nucleoside reverse
transcriptase
inhibitor (NRTI)
Alovudine FLT (3′-deoxy-3′-ﬂuorothymidine)
Didanosine ddI (2′,3′-dideoxyinosine)
Stavudine D4T (2′,3′-didehydro-2′,3′-
deoxythymidine)
Zalcitabine ddC (2′,3′-dideoxycytidine)
Zidovudine AZT (3′-azido-3′-deoxythymidine)
Protease inhibitor (PI) Indinavir IDV
Lopinavir LPV
Nelﬁnavir NFV
Ritonavir RTV
Saquinavir SQV
cause changes in gastrointestinal tract, liver, and kidney function
that collectively affect the pharmacology of administered drugs
(McLean and Le Couteur, 2004). None of these factors however
can directly be related to causing the premature and accelerated
aging phenotype witnessed in treated HIV-patients (Martin and
Volberding, 2010).
Most research in this relatively new ﬁeld focuses on how HIV-
1 infection depletes CD4+ cell counts and exhausts the patient’s
immune system (Appay and Sauce, 2008; Desai and Landay, 2010).
In this way, HIV-infection itself if left untreated has been shown
to convert the immune system of a young individual into one sim-
ilar to someone 40 years older (Ferrando-Martínez et al., 2011).
This theory of an accelerated aging process of the immune system
is called immunosenescence and is characterized by continu-
ous immune provocation and systemic low-grade inﬂammation,
which predisposes patients to co-morbidities and natural aging
symptoms more frequently seen in the elderly (Dock and Effros,
2011; Deeks et al., 2012).
The immunosenescence theory of aging has substance when
considering untreated patients, as it principally focuses on viral
effects. However, this theory is less plausible for treated patients
as HAART has proven highly successful in swiftly replenishing
CD4+ cell counts and reducing viral-load to barely detectable lim-
its (Camacho and Teóﬁlo, 2011). Additionally, various antivirals
have been shown to induce inﬂammatory signals and it is there-
fore plausible that if an altered immune-organization is seen in
HAART treated patients it is due to antiretroviral therapy (Mondal
et al., 2004; Lagathu et al., 2007; Lefèvre et al., 2010). The inﬂuence
HAART has warrants thorough investigation as HIV-patients take
HAARTdaily and for the rest of their lives. Very few premature and
accelerated aging studies in the HIV-infected population however,
focus upon the inﬂuence that antiretroviral drugs have on aging
and age-related co-morbidities. Accordingly, no consensus has
arisen as to why the successfully treated HIV-infected population
shows signs of premature and accelerated aging.
IS HAART THE PREDOMINANT CAUSE OF PREMATURE AND
ACCELERATED AGING?
Antiretroviral therapy as an explanation for premature and accel-
erated aging was ﬁrst mentioned in studies wherein clinical
symptoms of aging were shown to correlate with adverse side
effects of antiretroviral therapy (Onen et al., 2010). For exam-
ple, cardiovascular disease, diabetes, kidney and liver disease,
metabolic disorders, osteoporosis, and lipodystrophy have all been
associated with HAART (Effros et al., 2011; Klein, 2011). Accel-
erated Tau deposition, a marker for neurodegenerative diseases
such as Alzheimer’s and Parkinson’s, has also been shown to be
elevated in patients receiving HAART compared to HIV-infected
non-treated patients (Anthony et al., 2006). These symptoms col-
lectively seem to be related to tissues with high-energy demand
and show a strong similarity to hereditary mitochondrial dis-
eases (Schapira, 2012). Indeed, after introduction of HAART to
treat HIV-1 infection, it quickly became apparent that mitochon-
drial toxicity is a major reason for antiretroviral-related adverse
events (Brinkman et al., 1998). HAART-induced mitochondrial
dysfunction therefore likely plays a role in most, if not all compli-
cations associated with premature and accelerated aging (White,
2001; Hulgan and Gerschenson, 2012). The speciﬁc inﬂuence
of HAART upon mitochondria and aging however, is often not
addressed.
HAART-RELATED MITOCHONDRIAL TOXICITY IN AGING
Mitochondria are essential organelles in the life cycle and ﬁtness
of the cell. They are principal regulators of apoptosis and ATP
production. Mitochondria are also involved in calcium and reac-
tive oxygen species (ROS) homeostasis. Therefore, a perturbation
of any of these functions impairs cellular life-expectancy and has
been shown to have tissue and systemic repercussions including
accelerated aging (Trifunovic and Larsson, 2008). In consensus,
an accumulation of mitochondrial DNA (mtDNA) mutations,
increased mitochondrial oxidative stress and a decrease in mito-
chondrial energy metabolism are all important contributors to
aging (Lee and Wei, 2012). Mitochondria therefore play dominant
roles in aging and marked effects of HAART upon mitochondria
likely accelerate these effects. In this reviewwediscuss howHAART
is known to inﬂuence mtDNA integrity, alter mitochondrial mor-
phology and function, induce oxidative stress, inﬂammation, and
cell senescence, andhow it is directly connected to aging symptoms
and co-morbidities.
DRUG INDUCED ACCUMULATION OF mtDNA DAMAGE
Because mitochondria contain their own DNA, mitochondrial
genome integrity is essential for organelle function. The mtDNA
encodes vital components of the mitochondrial respiratory chain
and therefore damage to mtDNA is directly detrimental to energy
metabolism and organelle ﬁtness. Not surprisingly, cell senescence
and aging are associated with an increase in the amount of dam-
agedmtDNA.Additionally, accumulation of mutations inmtDNA
is known to increase with age, and aberrant mtDNA replica-
tion contributes to premature-and-accelerated-aging phenotypes
(Park and Larsson, 2011; Cline, 2012).
DNA damage and unreliable replication can be induced by the
backbone of antiretroviral therapy, namely NRTIs (Sundseth et al.,
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1996; Payne et al., 2011). NRTIs have been shown to inhibit the
mitochondrial speciﬁc DNA polymerase-γ causing a decrease in
mtDNA amount and quality. This discovery led to the theory of
NRTI-induced toxicity commonly known as the “polymerase-γ
theory” (Figure 2; Lewis and Dalakas, 1995). In short, a NRTI-
induced decrease inmtDNA leads tomalfunctioning of mitochon-
drial protein complexes and changes in respiration rate, decreased
ATP production, a diminished mitochondrial membrane poten-
tial, and an escalation in ROS production (Lewis et al., 2006;
Maagaard and Kvale, 2009). Besides direct inhibition of mtDNA
replication, NRTIs also obstruct base excision repair and proof-
reading capabilities of polymerase-γ (Lim and Copeland, 2001;
Lewis et al., 2003). Micewith impaired polymerase-γ proofreading
FIGURE 2 |The polymerase-γ theory. NRTIs compete with endogenous
nucleotides and nucleosides for transcriptase binding. Due to the surplus
and high afﬁnity of NRTIs for polymerase-γ, NRTIs are frequently
incorporated into the new DNA strand which results in chain termination as
they all lack the 3′-OH group necessary for phosphodiester bond formation
in DNA strand elongation. This results in a reduced number of mtDNA
molecules and possibly a reduction in mtDNA encoded proteins, essential
components of the mitochondrial respiratory chain (MRC) complexes. In
turn, this leads to disrupted electron transport through the MRC and a
concomitant reduction in proton efﬂux, reducing the membrane potential
and ATP production by the mitochondrion. This disturbed mitochondrial
function can result in augmented ROS production and morphological
changes. Disturbed mitochondrial function due to polymerase-γ inhibition
has been proposed as a central mechanism for NRTI-induced adverse
events (Lewis and Dalakas, 1995; Lewis et al., 2006).
ability show rapid accumulation of mtDNA mutations leading to
disrupted mitochondrial function, a variety of aging phenotypes
and early death (Trifunovic et al., 2004). Additionally, antiretrovi-
ral therapy likely hastens the expansion of pre-existing mutations
in mtDNA as depleted mtDNA pools display accelerated digres-
sion from their original genetic content (Khrapko, 2011; Payne
et al., 2011). The NRTI 3′-deoxy-3′-ﬂuorothymidine (alovudine
or FLT), known for its high toxicity, can cause DNA fragmenta-
tion and induce apoptosis (Sundseth et al., 1996). Interestingly, the
NRTIs 3′-azido-3′-deoxythymidine (zidovudine orAZT) and2′,3′-
didehydro-2′,3′-deoxythymidine (stavudine or d4T) also disrupt
telomerase maintenance and have telomere shortening effects,
properties often related to cell senescence and aging (Strahl and
Blackburn, 1994; Blasco, 2007).
During HAART it is very likely that NRTIs and PIs augment
each other’s ability to steer the cell into premature senescence. This
is especially the case when the“booster”PI ritonavir (RTV) is used
in the HAART cocktail. RTV impedes the enzyme cytochrome
P450-CYP3A4, which is responsible for the metabolism of xeno-
biotics, and therefore RTV induces an increase in intracellular
drug concentrations in the patient (Zeldin and Petruschke, 2004).
Interestingly, mtDNA damage has also been found to correlate
with PI RTV use in human endothelial cell cultures in a dose-
dependent manner (Zhong et al., 2002). Although mitochondria
are the most important players in antiretroviral toxicities, outside
these organelles PIs can cause accumulation of the farnesylated
pro-senescence protein prelamin A. Prelamin A accumulation has
been shown to cause genomic instability (Worman et al., 2009;
Reddy and Comai, 2012). Furthermore, PI-induced prelamin
A build-up is directly linked to increased oxidative stress and
lipodystrophy-associated symptoms (Caron et al., 2007).
Mitochondrial DNA quantity and quality are important fac-
tors in mitochondrial functionality, and therefore cellular ﬁtness,
as mtDNA encode for vital components of the organelle’s respi-
ratory chain complexes. Mitochondrial toxicity caused by NRTIs,
however, does not necessarily follow the chronological steps of the
polymerase-γ theory. Not every case of mtDNA depletion leads to
changed expression levels or activity of mitochondrial respiratory
chain proteins (Stankov et al., 2010). In addition, altered mito-
chondrial gene expression and impaired respiratory chain activity
have beenobservedwithoutmtDNAdepletion (Mallon et al., 2005;
Viengchareun et al., 2007). Expression proﬁles of mitochondrial
mRNApossibly explain these occurrences as they have been shown
to adjust, both in a peripheral blood mononuclear cell line and
mice upon exposure to NRTIs. These adjustments likely reﬂect
cellular adaptation to pressure on the mitochondrial transcrip-
tional machinery (d’Amati and Lewis, 1994; Papp et al., 2008). In
an elegant review, Apostolova et al. (2011a) show that mitochon-
drial toxicity of antiretroviral drugs goes beyond the polymerase-γ
theory as disruption of many other mitochondrial mechanisms is
also involved.
OXIDATIVE STRESS
Reactive oxygen species, especially superoxide and hydrogen per-
oxide, are habitually produced in small quantities bymitochondria
during oxidative phosphorylation. However, a decrease in, or mal-
function of, mitochondrial proteins, due to diminished mtDNA
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for instance, can disrupt electron ﬂow through the electron trans-
port chain and cause increased ROS formation (Brand, 2010).
Consequently, this increase in ROS can damage mitochondrial
components, such as the electron transport complexes, and hence
induce even more ROS production (Sastre et al., 2000). A fun-
damental feature of aging is a decline in mtDNA transcription
and repair capacity which can lead to mitochondrial malfunction
and set in motion a vicious cycle of enhanced ROS production
(Desler et al., 2011). Interestingly, polymerase-γ is highly sensitive
to oxidative damage and modiﬁcation of its amino acid residues
by oxidation brings about a decline in DNA-binding ability and
polymerase activity (Graziewicz et al., 2002).
An increase in oxidative stress, observed as increased oxidant
and reduced antioxidant levels in serum, has frequently been asso-
ciated with HAART in patients (Mandas et al., 2009). Several
studies conclude that symptoms of aging such as cardiovascular
disease, lipodystrophy, and insulin resistance are all inﬂuenced by
antiretrovirally induced ROS production (Day and Lewis, 2004;
Caron-Debarle et al., 2010). A common side effect of AZT, namely
cardiomyopathy, is likely caused by stimulation of ROSproduction
in heart and endothelial mitochondria (Sutliff et al., 2002; Valenti
et al., 2002). Prompt heart injury has even been ascribed largely
to 2′,3′-dideoxycytidine (zalcitabine or ddC) induced ROS pro-
duction, independent of mtDNA depletion or damage, a ﬁnding
that emphasizes the impact of antiretroviral-induced ROS toxicity
(Skuta et al., 1999). Increased oxidation of lipids, mtDNA and the
major antioxidant glutathione (GSH), further relate AZT to skele-
tal muscle myopathy (de la Asunción et al., 1998). d4T is known to
cause oxidative stress in human hepatoma cells and may underlie
hepatic steatosis and lactic acidosis, which are often experienced
by patients on HAART (Velsor et al., 2004). Thymidine analogs
have additionally been shown to cause cell senescence through
an increase in oxidative stress and induction of mitochondrial
dysfunction in human ﬁbroblast cell lines and in subcutaneous
adipose tissue from HAART patients (Caron et al., 2008).
Protease inhibitors also have the potential to induce oxidative
stress, although it is not always clear whether PI induced elevated
ROS is produced at the mitochondrial level. The most clearly PI
affected cell type is endothelial cells, although other cell types are
also afﬂicted, and strong connections exist between drug toxic-
ity and ROS production (Wang et al., 2007). RTV and lopinavir
(LPV), two frequently prescribed PIs, can increase ROS produc-
tion in human arterial endothelial cells (Lefèvre et al., 2010) and
are known to induce ROS through a perturbed mitochondrial
function in cardiomyocytes (Deng et al., 2010). Indinavir (IDV)
and nelﬁnavir (NFV) have been shown to elicit ROS produc-
tion in skin ﬁbroblast cultures in vitro and in patients’ adipose
tissue in vivo (Viengchareun et al., 2007). IDV and NFV have fur-
thermore been shown to cause ROS production in human aortic
endothelium and are thus involved in recruitment of mononuclear
cells and exacerbation of inﬂammation, prerequisites for vascular
complications (Mondal et al., 2004). Additionally, treatment with
IDV or NFV was shown to cause increased mitochondrial ROS
production and premature senescence in skin ﬁbroblasts (Caron
et al., 2007), and an IDV and AZT combination induces ROS
mediated apoptosis in human brain microvascular endothelial
cells (Manda et al., 2011). Short-term treatment of NFV increases
ROS generation and diminishes levels of GSH and the detoxiﬁ-
cation enzyme superoxide dismutase in a pancreatic insulinoma
cell line (Chandra et al., 2009). Moreover, NFV has been linked
to adipocyte insulin resistance through oxidative stress induced
apoptosis and necrosis (Vincent et al., 2004; Ben-Romano et al.,
2006), which is noteworthy as the anti-apoptotic properties of PIs
in a low-dose have been documented (Badley, 2005). Saquinavir
(SQV) however, was shown to cause apoptosis in human umbilical
vein endothelial cells via higher levels of ROS production (Baliga
et al., 2004). SQV, IDV, NFV, and RTV also elevate ROS in cere-
bral endothelial cells and interfere with proper blood brain barrier
maintenance. Therefore, these PIs conceivably play a signiﬁcant
role in antiretroviral-induced neurological symptoms and could
also increase viral entry into the central nervous system (Grigorian
et al., 2008). Collectively, these results indicate that oxidative stress
is a powerful driving force behind antiretroviral-induced toxic-
ity and has important roles in premature-and-accelerated-aging
symptoms (Blas-Garcia et al., 2011).
ALTERED MITOCHONDRIAL MORPHOLOGY AND FUNCTION
Mitochondria are no longer considered as static spherical bodies,
but highly dynamic organelles that readily fuse, divide, propagate,
and diminish according to cellular requirements. Mitochondrial
morphology plays an essential role inmtDNA rescue, protein qual-
ity control, and cell survival (Bess et al., 2012; Shutt and McBride,
2012). Certain distinct morphological changes in mitochondrial
structure and organization are therefore considered indicators of
aging in worms, mice, and humans (Jendrach et al., 2005; Yasuda
et al., 2006). Speciﬁcally, mitochondria of aged individuals are
often swollen and their structures contain less villous cristae, while
the mitochondrial network is frequently disrupted (Sastre et al.,
2000). Mitochondrial function, especially respiration and ATP
production, has beendemonstrated todeclinewith age and evenbe
an important mediator of senescence (Desler et al., 2012). Energy
deﬁciency can cause a broad range of metabolic and degenera-
tive diseases including aging (Wallace et al., 2010). Mitochondrial
processes for example play important roles in adipocyte differ-
entiation and function, which in turn inﬂuence a wide array of
homeostatic processes including insulin sensitivity and lipid accu-
mulation (Caron-Debarle et al., 2010). Changes in mitochondrial
structure and function are known to occur in age-associated disor-
ders such asParkinson’s disease, sarcopenia andmetabolic diseases,
including heart-disease and diabetes mellitus (Desler et al., 2012;
Galloway and Yoon, 2012).
Not surprisingly then, antiretroviral drugs are found to alter
mitochondrialmorphology and function, although speciﬁcmech-
anisms and the chronology of these events remain to be fully
unraveled. Electron microscopy of AZT-treated striated skele-
tal muscle from rats, and AZT-, ddC-, and 2′,3′-dideoxyinosine
(didanosine or ddI)-treated human hepatocytes show widespread
mitochondrial swelling with poorly organized cristae (Lewis et al.,
1992; Pan-Zhou et al., 2000). Muscle biopsies from AZT-treated
patients give similar results with striking variations in mitochon-
drial size, shape, and network organization (Pezeshkpour et al.,
1991). AZT and d4T induce a rapid increase in mitochondrial
proliferation in human ﬁbroblasts (Caron et al., 2008), and their
combination with or without IDV increase mitochondrial mass
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in both white and brown murine adipocytes (Viengchareun et al.,
2007). Individual exposure of HeLa cells to NFV, RTV, and SQV
caused fragmentationof themitochondrial network anddecreased
mitochondrial number and volume (Roumier et al., 2006).
Mitochondrial fusion, ﬁssion, and autophagy have important
roles in mitochondrial maintenance, speciﬁcally in protection
against persistent mtDNA damage (Chen et al., 2010; Bess et al.,
2012). Therefore, altered mitochondrial morphology might be
considered a compensatory mechanism to help preserve mito-
chondrial functions. Increased proliferation for example, may
be an attempt of mitochondria to recover mtDNA and increase
functional capacity under pressure (Lee and Wei, 2005). How-
ever, evidence exists that the newly formed mitochondria could be
non-functional (Caron et al., 2008). Mitochondrial autophagy on
the other hand, has been interpreted as a protective mechanism
against NNRTI efavirenz-induced respiratory chain malfunction
(Apostolova et al., 2011b).
Murine adipocytes exposed to AZT, d4T, and/or IDV dis-
played impaired mitochondrial function as measured by lower
respiration rate and decreased ATP production (Jiang et al., 2007;
Viengchareun et al., 2007). AZT is also known to competitively
inhibit the ADP/ATP antiporter in rat heart mitochondria and
thus could contribute to the ATP deﬁciency syndrome witnessed
in patients (Valenti et al., 2000). Cells with diminished oxidative
phosphorylation shift to glycolysis for their energy demandswhich
results in accumulation of lactate and, if left untreated, can cause
lactic acidosis. AZT-, d4T-, or ddC-treated human hepatoma
cells show increased lactate concentrations and, in some cases,
decreased activity of mitochondrial respiratory chain complexes
(Velsor et al., 2004). An analysis of mitochondrial genes in adipose
tissue and monocytes from HIV-negative subjects receiving dual
NRTI therapy revealed a signiﬁcant decrease in mitochondrial res-
piratory chain component expression (Mallon et al., 2005). AZT
and IDV have additionally been found to suppress membrane
potential and cause apoptosis in blood–brain barrier endothelial
cells (Manda et al., 2011). Moreover, PI-induced mitochondrial
effects are typically related to an altered membrane potential
(Apostolova et al., 2011a). A randomized, double-blind, placebo-
controlled study found that short-term AZT exposure reduced
mitochondrial function and insulin sensitivity in non-infected
participants (Fleischman et al., 2007). Additionally, a random-
ized clinical trial in non-symptomatic antiretroviral-naïve patients
showed that long-term exposure to PIs or NNRTIs is associ-
ated with disrupted glucose transport as well as disrupted lipid
metabolismwith increased insulin resistance (Shlay et al., 2007). In
conclusion, antiretroviral therapy has frequently been implicated
in metabolic diseases as a result of mitochondrial dysfunction
(Caron-Debarle et al., 2010) and mitochondrial impairment is
found in the absence of HIV infection.
IS HAART INVOLVED IN IMMUNOSENESCENCE?
With the success of HAART in viral suppression the question
arises whether HIV-1 is the sole plausible cause for immunose-
nescence in HIV-treated patients. HAART, which is taken daily
for lifelong periods, is probably also responsible for immune sys-
tem malfunction. Besides that various antivirals have been shown
to induce inﬂammatory signals (Mondal et al., 2004; Lagathu
et al., 2007; Lefèvre et al., 2010), senescent cells have also been
shown to change their phenotype, secreting proinﬂammatory
cytokines and contributing to systemic low-grade inﬂammation
(Freund et al., 2010). The systemic exposure and relatively high
concentration of antiretrovirals undoubtedly affects all cell types,
immune system cells included. The direct relationship between
antiretroviral drugs and inﬂammation needs to be addressed
further.
Hematopoietic progenitor and lymphoblastoid cell toxicity
of NRTIs may explain immune cell depletion independent of
inﬂammation (Faraj et al., 1994; Sundseth et al., 1996; Sharma,
2010). Moreover, a decline in mitochondrial genetic integrity
in hematopoietic progenitor cells could also explain continued
immune dysfunction upon cessation of therapy. mtDNA levels
do recover in patients after discontinuation of HAART (Côté
et al., 2002), but due to generation of somatic mutations by
antiretrovirals and ROS, it is likely that replenished mtDNA har-
bors mutations predisposing the recuperating mitochondria to
continued dysfunction.
A SUITABLE MODEL SYSTEM TO STUDY PREMATURE AND
ACCELERATED AGING
Many questions remain unanswered in the antiretroviral drug
ﬁeld. Most HIV-1-infected individuals use a numerous combi-
nation of antiretroviral drugs from two or more different classes,
making singular drug impacts difﬁcult to assess. Furthermore,
patient populations are diverse and administered drug cocktails as
well as research methods are often dissimilar (Fisher and Cooper,
2012). There are multiple in vivo and in vitro model systems in use
to study drug toxicity, however complex systems are time consum-
ing and expensive and they do not permit straightforward analysis.
Undeniably, the lack of a good model system has hampered con-
sistent and coherent research into speciﬁc effects of antiretroviral
therapy.
The nematode Caenorhabditis elegans has proven itself to be
one of the most versatile model organisms for the elucidation of
molecular pathways implicated in many human diseases, includ-
ing those of mitochondria and aging (Culetto and Sattelle, 2000;
Markaki and Tavernarakis, 2010). Aging in C. elegans is entirely
post-mitotic, reﬂecting the gradual loss of function in somatic cells
as they growold. Although limited, thismodel system can also help
researchers dissect tissue- and compartment-speciﬁc effects.C. ele-
gans normally has a relatively short lifespan of two weeks, enabling
researchers to rapidly assess the effects of different mutations
or treatments on lifespan. Mitochondrial research in C. elegans
has given us many insights into the genetic regulation of aging
and mitochondrial function, and it has provided us with a vast
array of mutants to study these effects (Tsang and Lemire, 2003;
Addo et al., 2010; Bratic et al., 2010). Not only is C. elegans a very
practical system, this nematode has also been used to study drug-
speciﬁc impact onmitochondria (Zubovych et al., 2010).With this
knowledge we can use C. elegans to quickly evaluate the effects of
individual antiretroviral drugs, not only on mitochondrial func-
tion directly, but in relation to organism genetics, physiology, and
longevity.
Caenorhabditis elegans has successfully been used to
elucidate speciﬁc effects of NRTIs on physiology and longevity
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FIGURE 3 | Schematic representation of the major effects of
antiretroviral drugs that drive premature and accelerated aging.
Antiretroviral drugs cause mtDNA damage and depletion, oxidative stress
and altered mitochondrial morphology and function. These alterations in the
mitochondria contribute, either alone or in unison, to premature and
accelerated aging in HAART-treated patients.
(R. de Boer and H. van der Spek, personal communication).
C. elegans demonstrated that NRTIs decrease mtDNA copy num-
ber, disrupt both structure and function of mitochondria and
shorten the average lifespan. Using oxygen consumption as a mea-
sure of mitochondrial function, NRTIs were shown to induce a
rapid decrease in mitochondrial ﬁtness. These ﬁndings compare
well to earlier studies wherein abnormal mitochondrial respira-
tory activity was correlated with altered expression or deﬁciency in
various respiratory chain complexes (Pan-Zhou et al., 2000; Caron
et al., 2008). Additionally, C. elegans mitochondria showed signs
of increased mass, fragmentation, and disrupted organization, as
is typically found in HAART treated patients (R. de Boer and H.
van der Spek, personal communication).
CONCLUSION
With the increase in life expectancy it has only recently become
clear that HIV-1 patients are suffering from symptoms of aging
ahead of time. In this review we postulate that strong correlations
exist between antiretroviral drug-induced mitochondrial toxic-
ity and premature and accelerated aging (Figure 3). However,
there are a number of questions that remain unanswered, sim-
ply because we do not fully understand the effects of antiretroviral
drugs individually, let alone in combination.
For example, questions remain about mitochondrial toxicity
of NRTIs beyond the polymerase-γ theory. Various cellular trans-
port systems interact with NRTIs and once inside the cell NRTIs
are actively phosphorylated from their pro-drug form (Lewis et al.,
2003). Changes in cellular thymidine kinase kinetics by interaction
with NRTI thymidine analogs have been linked to cardiomyopa-
thy and lipodystrophy (Apostolova et al., 2011a). Additionally, the
occasionally divergent relationship between mtDNA copy num-
ber and respiratory chain protein levels needs to be explained.
The inﬂuence NRTIs have on gene expression could give us
insight into cellular adaptation to antiretroviral drugs. Allevi-
ation of oxidative stress could prove an easy way to improve
the well-being of patients and delay the detrimental effects of
antiretroviral drugs. Interestingly, most of the above mentioned
ROS complications have experimentally been found to lessen
upon co-administration of antioxidant compounds. Antioxidant-
or mitochondria-directed supplementation may therefore beneﬁt
HAART patients, although thorough research remains to be done
before any deﬁnitive advice can be given to patients (Neustadt and
Pieczenik, 2008).
We propose the use of C. elegans as a model system to study
the effects of antiretroviral therapy on premature and accelerated
aging. Using C. elegans we can begin to study the effects of spe-
ciﬁc genetic backgrounds on HAART toxicities. Effects of HAART
seen in the nematode can directmore speciﬁc research into human
conditions. In addition,C. elegans could provide an easy platform,
not just for toxicity studies of various antiretroviral drugs, but also
to screen for suitable compounds that neutralize toxic effects of
HAART, which remains crucial as long as total HIV eradication is
not possible. Combining these genetic and toxicology approaches
we can initiate research leading to efﬁcient, personalized, anti-HIV
treatment in humans.
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